Compare KW & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KW | NRIX |
|---|---|---|
| Founded | 1977 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2007 | 2020 |
| Metric | KW | NRIX |
|---|---|---|
| Price | $10.91 | $15.82 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $11.00 | ★ $30.58 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 05-06-2026 | 04-10-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $62,633,000.00 | ★ $76,987,000.00 |
| Revenue This Year | $81.79 | N/A |
| Revenue Next Year | N/A | $26.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 23.94 | ★ 99.31 |
| 52 Week Low | $5.98 | $8.18 |
| 52 Week High | $10.99 | $22.50 |
| Indicator | KW | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 53.92 |
| Support Level | $10.82 | $14.61 |
| Resistance Level | $10.97 | $16.47 |
| Average True Range (ATR) | 0.05 | 0.90 |
| MACD | -0.03 | 0.14 |
| Stochastic Oscillator | 50.00 | 63.07 |
Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.